In the attempt to intensify the efficacy of an immunotherapy for HCC, double or triple checkpoints blockade such as anti PD-1 and anti CTLA-4 or anti PD-L1 and multi-target tyrosine kinase inhibitors have been suggested [83]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.